GPX1 and in situ carcinoma: The use of CIS markedly increased systemic and peripheral levels of proinflammatory cytokines (NF-κB1, TNF-α, IL-6) and oxidative stress markers (MDA, TOS, IMA), while decreasing antioxidant enzymes (CAT, GPx1, SOD2) and TAS.